

The lung cancer treatment landscape: Novel targets and treatment for improved patient care

Symposium Date / Time

12:00 – 13:00 JST/
Saturday, October 29, 2022

Venue

NARA Prefectural
Convention Center (204)

12:00-12:05

Opening

Chair / Moderator

Tetsuya Mitsudomi, MD, PhD

Specially-Appointed Professor,
Kindai Hospital Global Research Alliance Center and Thoracic Surgery, Kindai University

12:05-12:20

Molecular biomarker testing in clinical practice

Presenter

Yasushi Yatabe, MD, PhD

Chief, Department of Diagnostic Pathology / National Cancer Center Hospital

12:20-12:35

International trials of KRAS G12C inhibitors in NSCLC: Current state-of-the-art

Presenter

Bob Li, MD, PhD

Thoracic Oncology and Early Drug Development Service
Associate Professor, Weill Cornell Medicine, Cornell University
Co-Director, Thoracic Liquid Biopsy Program / Memorial Sloan Kettering Cancer Center

12:35-13:00

Panel Discussion

Presenter

Bob Li, MD, PhD

Thoracic Oncology and Early Drug Development Service
Associate Professor, Weill Cornell Medicine, Cornell University
Co-Director, Thoracic Liquid Biopsy Program / Memorial Sloan Kettering Cancer Center

Hidetoshi Hayashi, MD, PhD

Specially-Appointed Associate Professor,
Department of Medical Oncology, Kindai University

Yasushi Yatabe, MD, PhD

Chief, Department of Diagnostic Pathology
National Cancer Center Hospital

"This program was approved by the IASLC 2022 Asia Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2022 Asia Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program."

AMGEN[®]

Approved code : SC-JPN-AMG 510-00217
Approval date : Sep. 2022